PTTG Role in Ovarian Tumorigenesis and Matastasis
PTTG 在卵巢肿瘤发生和转移中的作用
基本信息
- 批准号:7998178
- 负责人:
- 金额:$ 24.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-03-26 至 2012-12-31
- 项目状态:已结题
- 来源:
- 关键词:5q35.1AddressAdenovirusesAneuploidyAnimal ModelAntineoplastic AgentsBase SequenceBoxingCancer ModelCause of DeathCell ProliferationCell SurvivalCellsCessation of lifeChromosomal InstabilityChromosome abnormalityChromosomesComplementary DNACrossbreedingCytoplasmDataDetectionDeveloped CountriesDevelopmentDown-RegulationEndometriumEnzyme-Linked Immunosorbent AssayEpithelial CellsEpitheliumFetal KidneyFetal LiverFibroblast Growth Factor 2Gene ExpressionGenesGeneticGenetically Engineered MouseGenomic InstabilityGrowthGynecologicHealthHumanIL8 geneIn VitroLaboratoriesLeadMaintenanceMalignant NeoplasmsMalignant neoplasm of ovaryMediatingMessenger RNAMethodsModelingMolecularMolecular CloningMolecular TargetMusMutationNeoplasm MetastasisNuclearNuclear ProteinsNude MiceOncogene ProteinsOncogenesOncogenicOvarianOvarian Surface Epithelial-Stromal TumorOvaryPI3K/AKTPTTG1 genePhenotypePreclinical TestingPreventionProcessProductionProline-Rich DomainProtein Sequence AnalysisProteinsReportingResearch PersonnelRoleSignal PathwaySister ChromatidSister Chromatid ExchangeSmall Interfering RNAStagingStructureSurfaceSystemTesticular NeoplasmsTestisTimeTransgenic AnimalsTransgenic MiceTumor SuppressionUnited StatesVascular Endothelial Growth FactorsWomanangiogenesisbasec-myc Genescancer diagnosiscell typeexpression vectorgene functionhuman PTTG1 proteinhuman tissuein vivoindexingknockout animalloss of functionmalignant breast neoplasmmetaplastic cell transformationmortalityneoplasticneoplastic cellnovelovarian neoplasmoverexpressionpituitary tumor-transforming proteinsprogramspromotersmall moleculetherapy developmenttumortumor growthtumor initiationtumorigenesistumorigenic
项目摘要
Ovarian cancer is the fifth most commonly diagnosed cancer among women and the most frequent cause of
death from gynecologic malignancies in the United States. Molecular mechanisms that initiate and support
ovarian tumorigenesis are not well defined. We cloned a novel oncogene "PTTG" also known as securin from
human testis and ovarian tumors and studied its function in tumorigenesis. PTTG is a multifunctional protein
and is highly expressed in many tumors, including tumors of ovary. Introduction of PTTG into NIH3T3 and
HEK293 cells induces cellular transformation and promotes tumor formation in nude mice, suggesting its
strong oncogenic function. Notably, PTTG has been shown to inhibit separation of sister chromatids, and to
increase the synthesis and secretion of bFGF, VEGF, and IL-8 as well as activate the expression of the
oncogene, c-myc and PI3K/AKT signaling pathway, suggesting that the oncogenic activity of PTTG may
involve induction of aneuploidy and chromosomal instability, increased angiogenesis, and production of
growth promoting oncogene products. Down-regulation of PTTG expression in ovarian tumor cells in vitro
and its deletion in animals (Knockout) results in reduction of tumor development, suggesting its important
role in maintenance of cancer phenotype. The long-term objectives of this application are to understand the
role of PTTG in ovarian tumorigenesis and validate PTTG as a molecular target for the development of anti-
neoplastic agents. In this application we propose: i) to determine the effect of overexpression of PTTG in
ovarian epithelial cells on cellular transformation and tumor development in nude mice; ii) to determine the
effect of overexpression of PTTG in ovarian surface epithelial cells on ovarian tumor initiation, progression
and metastasis in transgenic animals and determine mechanisms that support tumor growth and metastasis;
and iii)to determine the effect of down-regulation of PTTG expression in ovarian tumor cells on tumor
suppression and metastasis and determine mechanisms that lead to suppression of tumor growth and
metastasis. These studies will provide critical information regarding the mechanisms of PTTG in ovarian
tumorigenesis and metastasis and set up basis for the development of small molecules to inhibit PTTG
function as anti-neoplastic agents. In addition transgenic animal model developed from our studies could
enhance efforts aimed at developing new methods for detection, prevention, and treatment of ovarian cancer.
卵巢癌是女性第五大最常诊断的癌症,也是导致卵巢癌的最常见原因。
美国死于妇科恶性肿瘤的人数。启动和支持的分子机制
卵巢肿瘤的发生尚不明确。我们克隆了一种新的致癌基因“PTTG”,也称为 securin
人类睾丸和卵巢肿瘤并研究其在肿瘤发生中的功能。 PTTG是一种多功能蛋白质
在许多肿瘤中高表达,包括卵巢肿瘤。将PTTG引入NIH3T3并
HEK293细胞在裸鼠体内诱导细胞转化并促进肿瘤形成,表明其
强致癌功能。值得注意的是,PTTG 已被证明可以抑制姐妹染色单体的分离,并
增加 bFGF、VEGF 和 IL-8 的合成和分泌,并激活
癌基因、c-myc 和 PI3K/AKT 信号通路,表明 PTTG 的致癌活性可能
涉及非整倍体和染色体不稳定的诱导、血管生成的增加以及
促进生长的癌基因产品。体外卵巢肿瘤细胞PTTG表达下调
在动物中删除它(敲除)会导致肿瘤发展减少,这表明它的重要性
维持癌症表型的作用。该应用程序的长期目标是了解
PTTG 在卵巢肿瘤发生中的作用并验证 PTTG 作为开发抗卵巢肿瘤的分子靶点
肿瘤剂。在此应用中,我们建议:i) 确定 PTTG 过表达的影响
卵巢上皮细胞对裸鼠细胞转化和肿瘤发生的影响; ii) 确定
卵巢表面上皮细胞PTTG过表达对卵巢肿瘤发生、进展的影响
和转基因动物的转移,并确定支持肿瘤生长和转移的机制;
iii)确定卵巢肿瘤细胞中PTTG表达下调对肿瘤的影响
抑制和转移并确定导致抑制肿瘤生长和的机制
转移。这些研究将提供有关卵巢 PTTG 机制的重要信息
肿瘤的发生和转移,为开发抑制PTTG的小分子奠定基础
作为抗肿瘤剂。此外,我们的研究开发的转基因动物模型可以
加强努力开发检测、预防和治疗卵巢癌的新方法。
项目成果
期刊论文数量(13)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Tumorigenic potential of pituitary tumor transforming gene (PTTG) in vivo investigated using a transgenic mouse model, and effects of cross breeding with p53 (+/-) transgenic mice.
- DOI:10.1186/1471-2407-12-532
- 发表时间:2012-11-20
- 期刊:
- 影响因子:3.8
- 作者:Fong MY;Farghaly H;Kakar SS
- 通讯作者:Kakar SS
Synergistic cytotoxic action of cisplatin and withaferin A on ovarian cancer cell lines.
- DOI:10.1016/j.bbrc.2012.06.047
- 发表时间:2012-07-13
- 期刊:
- 影响因子:3.1
- 作者:Kakar, Sham S.;Jala, Venkatakrishna R.;Fong, Miranda Y.
- 通讯作者:Fong, Miranda Y.
Pituitary tumor transforming gene induces epithelial to mesenchymal transition by regulation of Twist, Snail, Slug, and E-cadherin.
- DOI:10.1016/j.canlet.2011.06.033
- 发表时间:2011-12-01
- 期刊:
- 影响因子:9.7
- 作者:Shah, Parag P.;Kakar, Sham S.
- 通讯作者:Kakar, Sham S.
Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer.
鉴定正常卵巢中的代谢产物及其在原发性和转移性卵巢癌中的转化。
- DOI:10.1371/journal.pone.0019963
- 发表时间:2011
- 期刊:
- 影响因子:3.7
- 作者:Fong MY;McDunn J;Kakar SS
- 通讯作者:Kakar SS
Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells.
- DOI:10.18632/oncotarget.20170
- 发表时间:2017-09-26
- 期刊:
- 影响因子:0
- 作者:Kakar SS;Parte S;Carter K;Joshua IG;Worth C;Rameshwar P;Ratajczak MZ
- 通讯作者:Ratajczak MZ
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sham S. Kakar其他文献
Journal of Ovarian Research reviewer acknowledgement 2015
- DOI:
10.1186/s13048-016-0215-1 - 发表时间:
2016-02-18 - 期刊:
- 影响因子:4.200
- 作者:
Sham S. Kakar;Stefano Palomba;Benjamin K. Tsang;David T. Curiel - 通讯作者:
David T. Curiel
Commentary: FSH and various forms of FSH receptors: distribution and their functions in gonads and extra-gonadal tissues
- DOI:
10.1186/s13048-021-00893-y - 发表时间:
2021-10-30 - 期刊:
- 影响因子:4.200
- 作者:
Sham S. Kakar;Mariusz Z. Ratajczak - 通讯作者:
Mariusz Z. Ratajczak
Ovarian cancer and the heart: pathophysiology, chemotherapy-induced cardiotoxicity, and new therapeutic strategies
- DOI:
10.1186/s13048-025-01636-z - 发表时间:
2025-04-05 - 期刊:
- 影响因子:4.200
- 作者:
Megha Nair;Arun Samidurai;Anindita Das;Sham S. Kakar;Rakesh C. Kukreja - 通讯作者:
Rakesh C. Kukreja
Withaferin A: a potential therapeutic agent against COVID-19 infection
- DOI:
10.1186/s13048-020-00684-x - 发表时间:
2020-07-19 - 期刊:
- 影响因子:4.200
- 作者:
Alex R. Straughn;Sham S. Kakar - 通讯作者:
Sham S. Kakar
PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer
- DOI:
10.1016/j.canlet.2024.217355 - 发表时间:
2025-01-28 - 期刊:
- 影响因子:
- 作者:
Sakthivel Muniyan;Raghupathy Vengoji;Rama Krishna Nimmakayala;Parthasarathy Seshacharyulu;Balaji Perumalsamy;Zahraa Wajih Alsafwani;Sham S. Kakar;Lynette M. Smith;Nicole Shonka;Benjamin A. Teply;Subodh M. Lele;Moorthy P. Ponnusamy;Surinder K. Batra - 通讯作者:
Surinder K. Batra
Sham S. Kakar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sham S. Kakar', 18)}}的其他基金
PTTG Role in Ovarian Tumorigenesis and Matastasis
PTTG 在卵巢肿瘤发生和转移中的作用
- 批准号:
7538374 - 财政年份:2007
- 资助金额:
$ 24.55万 - 项目类别:
PTTG Role in Ovarian Tumorigenesis and Matastasis
PTTG 在卵巢肿瘤发生和转移中的作用
- 批准号:
7754388 - 财政年份:2007
- 资助金额:
$ 24.55万 - 项目类别:
PTTG Role in Ovarian Tumorigenesis and Matastasis
PTTG 在卵巢肿瘤发生和转移中的作用
- 批准号:
7179641 - 财政年份:2007
- 资助金额:
$ 24.55万 - 项目类别:
PTTG Role in Ovarian Tumorigenesis and Matastasis
PTTG 在卵巢肿瘤发生和转移中的作用
- 批准号:
7389540 - 财政年份:2007
- 资助金额:
$ 24.55万 - 项目类别:
MOLECULAR MECHANISMS OF HTTG IN OVARIAN TUMORS
HTTG 在卵巢肿瘤中的分子机制
- 批准号:
2885542 - 财政年份:1999
- 资助金额:
$ 24.55万 - 项目类别:
MOLECULAR MECHANISMS OF HTTG IN OVARIAN TUMORS
HTTG 在卵巢肿瘤中的分子机制
- 批准号:
6174251 - 财政年份:1999
- 资助金额:
$ 24.55万 - 项目类别:
MOLECULAR MECHANISMS OF HTTG IN OVARIAN TUMORS
HTTG 在卵巢肿瘤中的分子机制
- 批准号:
6454939 - 财政年份:1999
- 资助金额:
$ 24.55万 - 项目类别:
MOLECULAR MECHANISMS OF HTTG IN OVARIAN TUMORS
HTTG 在卵巢肿瘤中的分子机制
- 批准号:
6364393 - 财政年份:1999
- 资助金额:
$ 24.55万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 24.55万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 24.55万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 24.55万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 24.55万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 24.55万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 24.55万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 24.55万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 24.55万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 24.55万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 24.55万 - 项目类别:
Research Grant














{{item.name}}会员




